
    
      This is a multicenter, double-blind study in up to 750 participants, who will be randomized
      to receive subcutaneous (SC) injections of either AKCEA-TTR-LRx or placebo once every 4
      weeks. Participants will also receive daily supplemental doses of the recommended daily
      allowance of vitamin A.
    
  